Available online on 15.12.2025 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2025 The   Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access Full Text Article                                                                           Review Article

Solid lipid nanoparticles: a promising platform for controlled and targeted drug delivery

Manikanta Chikka, K. Anie Vijetha, M. Sunitha Reddy *

Centre for Pharmaceutical Sciences, University College of Pharmaceutical Sciences, JNTUH, Sultanpur, Hyderabad, Telangana State, India-500085

 

1. Introduction

The integration of nanotechnology into drug delivery systems has revolutionized modern pharmaceutical science by offering novel solutions to longstanding challenges such as poor solubility, limited bioavailability, instability, and non-specific targeting of drugs. Nanocarrier-based delivery platforms enable enhanced drug solubilization, improved pharmacokinetics, and the possibility of site-specific targeting. These systems, typically within the size range of 10 to 1000 nm, provide a large surface area, tailored surface characteristics, and controlled drug release properties, which are particularly beneficial in chronic and complex diseases such as cancer, neurodegenerative disorders, and infectious diseases^1-3.

Among the various nanocarriers explored—including liposomes, niosomes, polymeric nanoparticles, and dendrimers—Solid Lipid Nanoparticles (SLNs) have garnered considerable attention due to their distinct advantages. SLNs are submicron colloidal carriers composed of physiological lipids that remain solid at both room and body temperatures, stabilized by suitable surfactants. First introduced in the 1990s as an alternative to traditional carriers, SLNs combine the benefits of lipid emulsions and polymeric nanoparticles while minimizing their respective drawbacks^4-6.

Compared to liposomes, SLNs exhibit superior physical stability and avoid issues related to phospholipid degradation. Unlike polymeric nanoparticles, which may involve the use of toxic monomers and organic solvents, SLNs are composed of biocompatible and biodegradable lipids, making them safer and more acceptable for clinical applications. Additionally, SLNs protect labile drugs from enzymatic and chemical degradation, allow for controlled drug release, and have the potential to be produced on an industrial scale using cost-effective and scalable methods such as high-pressure homogenization^7,8.

The unique properties of SLNs—such as high drug loading, enhanced permeability, and compatibility with various administration routes (oral, parenteral, topical, pulmonary)—make them promising candidates for improving therapeutic outcomes. As research progresses, SLNs are evolving into more advanced platforms such as nanostructured lipid carriers (NLCs) and lipid-polymer hybrid nanoparticles, expanding their scope and utility in drug delivery^9,10.

2. Composition of Solid Lipid Nanoparticles (SLNs)

The formulation of solid lipid nanoparticles (SLNs) involves a combination of lipids, surfactants, co-surfactants, and sometimes co-solvents. Each of these components plays a crucial role in determining the stability, size, drug loading efficiency, and release profile of the nanoparticles. A carefully selected composition is vital to optimize the therapeutic potential of SLNs.

2.1 Types of Lipids

Lipids form the core matrix of SLNs and are responsible for entrapping the drug molecules. They remain solid at both room and body temperatures, providing a stable structure. Commonly used lipids include:

• Glyceryl monostearate (GMS): A monoacylglycerol widely used due to its emulsifying properties and ability to provide controlled release.
• Stearic acid: A saturated long-chain fatty acid known for its high melting point and biocompatibility. It contributes to the rigidity and stability of the SLN matrix.
• Compritol® 888 ATO (glyceryl behenate): Offers a stable solid matrix with high drug entrapment capacity.
• Precirol® ATO 5 (glyceryl palmitostearate): Frequently used for sustained drug release applications.
• Cetyl palmitate, tripalmitin, and tristearin: These triglycerides and waxes are also used depending on the desired release profile and compatibility with the active ingredient.

The selection of lipid influences drug encapsulation, crystallinity, polymorphic transitions, and drug release kinetics^11-15.

2.2 Surfactants and Co-surfactants

Surfactants stabilize the SLNs by reducing interfacial tension and preventing aggregation. They also influence particle size and zeta potential. Examples include:

• Tween 80 (Polysorbate 80): A widely used non-ionic surfactant that enhances particle stability and prevents aggregation.
• Poloxamer 188: A block copolymer surfactant known for its excellent stabilizing effect and biocompatibility.
• Lecithin (phosphatidylcholine): A natural emulsifier that enhances the entrapment efficiency and reduces toxicity.
• Span 60 (Sorbitan monostearate): Often used in combination with other surfactants for stability.

Co-surfactants such as PEG 400 or Transcutol P are sometimes included to improve the flexibility of the surfactant layer and promote drug solubilization.

The surfactant concentration must be optimized; too little may lead to particle aggregation, while excessive amounts may lead to toxicity or poor drug loading^14-18.

2.3 Co-solvents and Their Roles

Co-solvents are incorporated in SLN formulations to improve the solubility of poorly water-soluble drugs and enhance the fluidity of the formulation during processing. They also facilitate the uniform distribution of the drug within the lipid matrix. Common co-solvents include:

• Ethanol: Frequently used in hot homogenization methods; it improves drug solubilization and evaporation after processing.
• Propylene glycol and polyethylene glycol (PEG 400): These are non-toxic, water-miscible solvents that aid in reducing particle size and improving emulsification.

The choice of co-solvent depends on the drug’s solubility profile, compatibility with lipids, and the method of preparation^19,20.

3. Methods of Preparation of Solid Lipid Nanoparticles (SLNs)

The method of preparation significantly affects the physicochemical characteristics of SLNs, such as particle size, drug entrapment efficiency, and stability. Various techniques have been developed, each with its own merits and limitations. The most commonly used methods are high-pressure homogenization, solvent emulsification-evaporation, microemulsion-based techniques, and ultrasonication.

3.1 High-Pressure Homogenization (Hot and Cold Techniques)

High-pressure homogenization is one of the most widely used and scalable techniques for SLN production. It involves the use of high shear forces to reduce particle size and ensure uniform dispersion.

• Hot Homogenization: The lipid is melted above its melting point and the drug is dissolved or dispersed in it. This lipid melt is then emulsified with an aqueous surfactant solution of the same temperature. The pre-emulsion is subjected to high-pressure homogenization followed by cooling to form SLNs. It is suitable for heat-stable drugs.
• Cold Homogenization: Ideal for thermolabile drugs. The drug is dispersed in the melted lipid, rapidly cooled (usually in liquid nitrogen or dry ice), and ground into lipid microparticles. These are then dispersed in a cold surfactant solution and homogenized at or below room temperature. This method reduces the risk of thermal degradation and drug loss^21-26.

3.2 Solvent Emulsification-Evaporation Technique

This method involves dissolving both lipid and drug in a water-immiscible organic solvent (like chloroform or ethyl acetate). The organic phase is emulsified into an aqueous surfactant solution under high-speed stirring to form an o/w emulsion. The solvent is then evaporated under reduced pressure, leading to lipid precipitation in the form of nanoparticles.

This technique is simple and suitable for lipophilic drugs but has limitations due to the use of organic solvents, which may pose regulatory and safety issues^22-24.

3.3 Microemulsion-Based Method

Microemulsion-based SLN preparation is a low-energy, thermodynamically driven process. It involves preparing a hot microemulsion of molten lipid, surfactant, co-surfactant, and water. This microemulsion is then dispersed in cold water (2–4°C), which leads to precipitation of lipid droplets as SLNs due to sudden cooling.

This method is simple and does not require sophisticated equipment, but the use of high surfactant concentrations may limit its pharmaceutical acceptability for parenteral routes^25-27.

3.4 Ultrasonication and Other Emerging Techniques

• Ultrasonication (or Probe Sonication): This method uses ultrasonic energy to reduce the particle size of a pre-emulsion. It is a simple, lab-scale method that avoids the need for high-pressure homogenizers. However, metal contamination from the probe and less control over size distribution are limitations.
• Other Emerging Techniques:
  1. Spray drying and lyophilization are used for converting SLN dispersions into dry powder form for stability.
  2. Supercritical fluid technology is gaining interest as a solvent-free, eco-friendly method.
  3. Double emulsification (w/o/w) techniques are employed for hydrophilic drug entrapment.

Each method must be selected based on the nature of the drug, desired particle size, entrapment efficiency, scalability, and regulatory considerations^28-30.

4. Characterization of Solid Lipid Nanoparticles (SLNs)

Comprehensive characterization of SLNs is crucial to evaluate their physicochemical properties, predict their biological performance, and ensure reproducibility and stability. The following parameters are commonly assessed:

4.1 Particle Size, Polydispersity Index (PDI), and Zeta Potential

• Particle Size determines drug release behavior, cellular uptake, and biodistribution. SLNs typically range between 50–500 nm.
• Polydispersity Index (PDI) reflects size uniformity. A PDI below 0.3 indicates a narrow size distribution, which is ideal for pharmaceutical formulations.
• Zeta Potential indicates surface charge and is critical for physical stability. Values above ±30 mV typically ensure electrostatic repulsion, preventing particle aggregation.

These parameters are usually determined using Dynamic Light Scattering (DLS) or photon correlation spectroscopy^31-34.

4.2 Entrapment Efficiency (%EE) and Drug Loading (%DL)

• Entrapment Efficiency (%EE) refers to the percentage of drug successfully encapsulated within the lipid matrix.
• Drug Loading (%DL) indicates the amount of drug per unit weight of nanoparticles.

These are calculated using ultracentrifugation or dialysis methods followed by spectrophotometric or HPLC analysis. High EE and DL values are desired for therapeutic efficiency and cost-effectiveness^35-36.

4.3 Morphology (Scanning Electron Microscopy / Transmission Electron Microscopy)

• SEM (Scanning Electron Microscopy) and TEM (Transmission Electron Microscopy) are used to study the shape and surface characteristics of SLNs.
• SEM offers surface topography, while TEM provides internal structure details and confirms spherical morphology.

Morphological evaluation supports data from particle size measurements and gives visual confirmation of nanoparticle uniformity and integrity^32,34.

4.4 Crystallinity and Physical State (PXRD and DSC)

• PXRD (Powder X-ray Diffraction) helps in understanding the crystalline nature of SLNs and drug. A reduction in crystallinity or disappearance of characteristic peaks of the drug in PXRD patterns indicates successful drug entrapment in an amorphous or molecularly dispersed form.
• DSC (Differential Scanning Calorimetry) provides thermal behavior and melting point information. A shift or disappearance of melting endotherms suggests the transformation of the drug from crystalline to amorphous state or its solubilization in lipid matrix.

These studies help in confirming physical stability and drug incorporation behavior^34-37.

4.5 Stability Studies

Stability evaluation is essential to assess changes in particle size, PDI, zeta potential, drug content, and appearance over time. Accelerated stability studies, typically conducted at 40 ± 2 °C and 75 ± 5% RH as per ICH guidelines, simulate long-term storage conditions.

Parameters are evaluated at regular intervals (e.g., 0, 1, 3, and 6 months). Consistent values indicate good formulation stability, crucial for commercial application^38-40.

 

5. Drug Incorporation Models

In Solid Lipid Nanoparticles (SLNs), drug incorporation is a critical aspect that determines the release profile, stability, and bioavailability of the therapeutic agent^41-43. Depending on the formulation conditions and drug solubility in the lipid phase, drugs can be incorporated into SLNs using one of the following models:

Homogeneous Matrix Model

In this model, the drug is uniformly dispersed throughout the lipid matrix. This usually occurs when the drug is soluble in the melted lipid during preparation or precipitates simultaneously with the lipid during cooling. The homogeneous matrix model is often achieved through high-pressure homogenization or solvent emulsification methods. This configuration provides a sustained drug release as the matrix erodes or degrades gradually, releasing the drug consistently over time. It is particularly suitable for low-dose, hydrophobic drugs that require prolonged therapeutic action^42-46.

Drug-Enriched Shell or Core Models

Drug-Enriched Core Model: This occurs when the drug precipitates first during the cooling phase before the lipid recrystallizes. As a result, the drug is mainly concentrated in the core of the nanoparticle, surrounded by a lipid shell. This model is preferred when a burst release is needed initially, followed by a controlled release.

Drug-Enriched Shell Model: In this case, the lipid solidifies before the drug during cooling, leading the drug to concentrate in the outer shell of the SLN. This arrangement results in a faster release of the drug due to its surface localization, making it ideal for rapid therapeutic effects^47-50.

6. Applications in Drug Delivery

Solid Lipid Nanoparticles (SLNs) offer versatile applications across various routes of drug administration due to their biocompatibility, controlled drug release, and enhanced drug stability^51-59. Their ability to encapsulate both hydrophilic and lipophilic drugs makes them ideal carriers for therapeutic agents in numerous delivery systems.

1. Oral Drug Delivery

SLNs are increasingly used in oral drug delivery to improve the solubility and bioavailability of poorly water-soluble drugs. They protect labile drugs from acidic gastric environments and enzymatic degradation in the gastrointestinal tract. Additionally, SLNs facilitate lymphatic uptake and bypass first-pass metabolism, resulting in higher systemic availability.

2. Topical Drug Delivery

SLNs enhance skin penetration and provide a controlled release of drugs for topical applications. They form an occlusive film over the skin, which increases skin hydration and drug retention. This is particularly beneficial for dermatological conditions like acne, psoriasis, or fungal infections, where prolonged drug action is desired with minimal systemic absorption.

3. Parenteral Drug Delivery

For intravenous or intramuscular delivery, SLNs provide a stable and safe platform for delivering chemo-therapeutic agents, antibiotics, or hormones. They improve the pharmacokinetic profiles of drugs, reduce systemic toxicity, and enhance circulation time, especially when surface-modified with PEG or ligands for targeted delivery.

4. Pulmonary Drug Delivery

SLNs are being explored for pulmonary delivery via nebulization or dry powder inhalers. They improve drug deposition in the lungs and protect drugs from degradation. SLNs also offer potential in the treatment of respiratory diseases like asthma, tuberculosis, and cystic fibrosis.

5. Use in Cancer Therapy

SLNs have shown significant promise in oncology due to their ability to deliver anticancer agents directly to tumor cells while minimizing systemic toxicity. Surface modification with ligands enables active targeting of tumor-specific receptors. Controlled release of drugs like paclitaxel, doxorubicin, and ibrutinib through SLNs enhances therapeutic efficacy and reduces side effects.

6. CNS Disorders

Crossing the blood-brain barrier (BBB) is a major challenge in CNS drug delivery. SLNs, due to their small size and lipid-based nature, can cross the BBB effectively. They have been used to deliver antiepileptics, antidepressants, and neuroprotective agents for treating neurological conditions such as Parkinson’s and Alzheimer’s disease.

7. Vaccines

SLNs have been investigated as adjuvants and carriers for vaccine delivery. They help protect antigens from degradation, improve immune response, and enable controlled antigen release. Their biocompatibility and ability to be administered through various routes make them suitable for modern vaccine formulations.

7. Recent Advances and Future Perspectives

Solid Lipid Nanoparticles (SLNs) have evolved significantly since their inception, with continuous research leading to innovative adaptations and advanced delivery platforms. These developments aim to overcome limitations associated with conventional SLNs, such as low drug-loading capacity or drug expulsion during storage^60-62. Recent advances have improved SLN performance in terms of drug encapsulation, release profiles, targeting, and clinical application potential.

1. Hybrid Lipid Nanoparticles

Hybrid lipid nanoparticles are one of the most promising innovations in the field. These systems combine solid lipids with liquid lipids (oils) to form Nanostructured Lipid Carriers (NLCs). NLCs offer improved drug-loading capacity, better physical stability, and minimized drug leakage compared to traditional SLNs. The incorporation of liquid lipids disrupts the perfect crystalline structure of solid lipids, creating more imperfections to accommodate the drug molecules. Additionally, polymers or inorganic materials can also be hybridized with lipids to enhance functionality such as responsiveness to pH, temperature, or magnetic fields for smart drug delivery.

2. SLN-Loaded Hydrogels or Microneedles

The integration of SLNs into hydrogels or microneedle arrays has shown significant promise for transdermal and localized drug delivery. Hydrogels serve as biocompatible scaffolds that can entrap SLNs and provide sustained release when applied to the skin, eyes, or mucosa. SLN-loaded microneedles, on the other hand, offer a minimally invasive strategy for delivering SLNs across the stratum corneum barrier into the dermis. This hybrid system allows for improved drug permeability, controlled release, and patient-friendly administration, particularly for vaccines, insulin, or anti-cancer drugs.

3. Clinical Status and Regulatory Aspects

Although numerous SLN-based formulations have demonstrated impressive preclinical results, only a few have advanced to clinical trials. Challenges such as scale-up, reproducibility, long-term stability, and regulatory compliance remain key barriers to clinical translation. Regulatory bodies such as the FDA and EMA have established frameworks for nanomedicines, but standardized guidelines specifically for SLNs are still evolving. Ensuring batch-to-batch consistency, demonstrating safety and efficacy through robust clinical studies, and employing Good Manufacturing Practices (GMP) are critical for regulatory approval.

Despite these hurdles, several SLN-based products (mainly for topical delivery) have entered the market, such as Revitalift® (cosmetic SLN cream) and NLC-based sunscreen formulations, reflecting their commercial viability. With the advent of personalized medicine and increasing demand for targeted delivery systems, SLNs are well-positioned to contribute significantly to the next generation of nanotherapeutics.

8. Conclusion

Solid Lipid Nanoparticles (SLNs) have emerged as a versatile and promising nanocarrier system for drug delivery, offering a unique combination of advantages such as biocompatibility, controlled release, enhanced stability, and scalability. With the ability to encapsulate both hydrophilic and lipophilic drugs, SLNs serve as effective alternatives to conventional carriers like liposomes and polymeric nanoparticles. Their application spans across various routes of administration—oral, topical, parenteral, and pulmonary—and therapeutic areas including cancer, CNS disorders, infections, and vaccination.

The advances in lipid selection, surfactant optimization, and formulation techniques such as high-pressure homogenization, ultrasonication, and microemulsion methods have significantly improved the efficiency and versatility of SLNs. Characterization techniques like DLS, PXRD, FTIR, and DSC further ensure quality and performance consistency, which is crucial for clinical translation.

Recent innovations, such as hybrid lipid nanoparticles, SLN-loaded hydrogels, and microneedle delivery systems, have expanded the scope of SLNs, enabling targeted and site-specific delivery. However, challenges like low drug loading for some drugs, drug expulsion during storage, and regulatory standardization still need to be addressed.

SLNs hold great promise in the era of personalized medicine and nanotheranostics. With ongoing research and refinement in formulation science, coupled with advancements in regulatory pathways, SLNs are poised to revolutionize drug delivery by improving therapeutic outcomes, minimizing side effects, and enhancing patient compliance.

Conflict of Interest: The authors declare no potential conflict of interest concerning the contents, authorship, and/or publication of this article.

Author Contributions: All authors have equal contributions in the preparation of the manuscript and compilation.

Source of Support: Nil

Funding: The authors declared that this study has received no financial support.

Informed Consent Statement: Not applicable. 

Data Availability Statement: The data supporting this paper are available in the cited references. 

Ethical approval: Not applicable.

References:

1. Pardeike J, Weber S, Hommoss A, Advances in nanostructured and solid lipid carriers for targeted drug delivery: Trends and translational potential, Advanced Drug Delivery Reviews, 2025; 207:115132.

2. Khan MA, Rehman S, Alam M, Solid lipid nanoparticles in cancer therapy: Recent progress and emerging challenges, Journal of Controlled Release, 2024; 368:250-266.

3. Sharma R, Gupta A, Jain R, Formulation and stability evaluation of SLNs for oral delivery of poorly soluble drugs, International Journal of Pharmaceutics, 2024; 647:123456.

4. Alam T, Beg S, Rahman M, Lipid-based nanocarriers for brain targeting: Focus on solid lipid nanoparticles and nanostructured lipid carriers, Colloids and Surfaces B: Biointerfaces, 2023; 228:113420.

5. Dai C, Wang B, Zhang S, Hybrid solid lipid nanoparticles for controlled drug release: Mechanistic insights and application potential, Materials Science & Engineering C, 2023; 149:112391.

6. Kumari N, Kaur P, Singh B, Solid lipid nanoparticles incorporated in hydrogels for topical drug delivery: Innovations and future perspectives, Drug Development and Industrial Pharmacy, 2022; 48(10):1556-1568.

7. Liu Y, Zhang H, Chen X, Design and evaluation of SLN-loaded microneedle patches for transdermal drug delivery, European Journal of Pharmaceutics and Biopharmaceutics, 2022; 178:32-45.

8. Souto EB, Silva AM, Müller RH, Lipid nanoparticles for dermal and transdermal drug delivery: An update, Pharmaceutics, 2022; 14(2):342.

9. Mohamed ME, El-Refaie WM, Abdel-Mottaleb MMA, Nanostructured lipid carriers and SLNs for ocular drug delivery: Recent findings and future directions, Expert Opinion on Drug Delivery, 2021; 18(6):821-836.

10. Wong CY, Martinez J, Goh BH, Solid lipid nanoparticles for enhanced delivery of bioactives: Formulation optimization and characterization, Nanomedicine, 2021; 36:102432.

11. Shah, R. M., Eldridge, D. S., Palombo, E. A., & Harding, I. H.Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique. Journal of Colloid and Interface Science, 2014; 428:286-294. https://doi.org/10.1016/j.jcis.2014.04.019 PMid:24863799

12. Patel A, Desai N, Parmar G, Solid lipid nanoparticles for enhanced oral bioavailability of hydrophobic drugs: Recent advances, International Journal of Pharmaceutics, 2025; 635:122987.

13. Rai V, Kaur P, Singh G, Lipid-based nanocarriers for targeted cancer drug delivery: A focus on solid lipid nanoparticles, Journal of Controlled Release, 2024; 372:456-472.

14. Bhandari R, Kumar S, Mehta T, Optimization and characterization of solid lipid nanoparticles for transdermal drug delivery, Colloids and Surfaces B: Biointerfaces, 2024; 230:113521.

15. Zhang L, Chen X, Li Y, Progress in hybrid solid lipid nanoparticles for improved drug loading and controlled release, Materials Science & Engineering C, 2023; 150:112700.

16. Sundaramoorthy P, Reddy K, Srivastava A, Solid lipid nanoparticles for brain targeting: Design strategies and recent updates, Drug Delivery and Translational Research, 2023; 13(4):1452-1468.

17. Garg A, Chauhan H, Singh J, Advanced characterization techniques for solid lipid nanoparticles: A comprehensive review, Journal of Drug Delivery Science and Technology, 2022; 77:103902.

18. Monteiro LM, Oliveira AC, Costa JF, Solid lipid nanoparticles for topical and transdermal applications: An updated review, Pharmaceutics, 2022; 14(9):1820.

19. Devi B, Rawat M, Pandey P, Development and evaluation of SLNs for improved bioavailability of poorly soluble drugs, Journal of Pharmaceutical Investigation, 2022; 52(3):341-354.

20. Hossen MN, Kajani AA, Rahman MT, Solid lipid nanoparticles and nanostructured lipid carriers in vaccine delivery: Recent perspectives, Advanced Drug Delivery Reviews, 2021; 178:113943.

21. Raza K, Singh B, Lohan S, Solid lipid nanoparticles for enhanced oral delivery of anticancer drugs: Design and evaluation, Colloids and Surfaces B: Biointerfaces, 2025; 235:113947.

22. Tiwari A, Sharma P, Jain A, Recent advances in SLN-based transdermal delivery systems: Formulation to clinical translation, Advanced Drug Delivery Reviews, 2024; 210:115402.

23. Ogunsola OE, Adebayo AS, Yusuf AA, Formulation and optimization of curcumin-loaded solid lipid nanoparticles for improved bioavailability, Journal of Pharmaceutical Sciences, 2024; 113(5):1874-1886.

24. Martins C, Pereira I, Costa R, Lipid-based nanoparticles for targeted cancer therapy: A comprehensive review, European Journal of Pharmaceutics and Biopharmaceutics, 2023; 186:54-72.

25. Ibrahim SS, Hassan Y, El-Mahdy M, Development and characterization of SLNs for enhanced delivery of antifungal drugs, Drug Delivery, 2023; 30(2):351-364.

26. Pandey S, Gupta M, Dubey V, Solid lipid nanoparticles for lymphatic targeting: Opportunities and challenges, Nanomedicine, 2022; 17(8):623-639.

27. Seo JH, Lee HJ, Kim SY, SLN-based intranasal delivery systems for CNS drugs: Trends and future perspectives, Pharmaceutics, 2022; 14(10):2140. https://doi.org/10.3390/pharmaceutics14061272 PMid:35745844 PMCid:PMC9231122

28. Chakraborty S, Ghosh A, Maiti S, Fabrication of SLNs using green synthesis: Applications in drug delivery, Journal of Drug Delivery Science and Technology, 2022; 78:103950.

29. Moghaddasi L, Tamaddon AM, Dinarvand R, Nanostructured lipid carriers and solid lipid nanoparticles for peptide delivery: Current status and prospects, Expert Opinion on Drug Delivery, 2021; 18(12):1733-1750.

30. Elnaggar YSR, El-Massik MA, Abdallah OY, Solid lipid nanoparticles as advanced carriers for topical formulations: Recent developments, AAPS PharmSciTech, 2021; 22(7):254.

31. Elkomy M, Elsheikh MA, Helmy MW, Formulation and in-vitro evaluation of SLNs for enhanced transdermal delivery of anti-inflammatory drugs, European Journal of Pharmaceutics and Biopharmaceutics, 2021; 165:162-171.

32. Srujana S, Anjamma M, Alimuddin, Singh B, Dhakar RC, Natarajan S, Hechhu R. A Comprehensive Study on the Synthesis and Characterization of TiO2 Nanoparticles Using Aloe vera Plant Extract and Their Photocatalytic Activity against MB Dye. Adsorption Science & Technology. 2022;2022 https://doi.org/10.1155/2022/7244006

33. Muller RH, Radtke M, Wissing SA, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Advanced Drug Delivery Reviews, 2002; 54(S1):S131-S155. https://doi.org/10.1016/S0169-409X(02)00118-7 PMid:12460720

34. Das S, Ng WK, Kanaujia P, Kim S, Tan RBH, Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: Effects of process variables, Colloids and Surfaces B: Biointerfaces, 2012; 88(2):483-489. https://doi.org/10.1016/j.colsurfb.2011.07.036 PMid:21831615

35. Almeida H, Amaral MH, Lobão P, Lobo JMS, Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: Present and future considerations, Journal of Pharmacy & Pharmacology, 2014; 66(4):477-491.

36. Uner M, Yener G, Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives, International Journal of Nanomedicine, 2007; 2(3):289-300.

37. Patravale VB, Date AA, Kulkarni RM, Nanosuspensions: A promising drug delivery strategy, Journal of Pharmacy and Pharmacology, 2004; 56(7):827-840. https://doi.org/10.1211/0022357023691 PMid:15233860

38. Shah S, Patel D, Patel R, Parmar K, A review on solid lipid nanoparticles: A promising drug delivery system, International Journal of Pharmaceutical Sciences and Research, 2016; 7(2):443-453.

39. Mukherjee S, Ray S, Thakur RS, Solid lipid nanoparticles: A modern formulation approach in drug delivery system, Indian Journal of Pharmaceutical Sciences, 2009; 71(4):349-358. https://doi.org/10.4103/0250-474X.57282 PMid:20502539 PMCid:PMC2865805

40. Müller RH, Mäder K, Gohla S, Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art, European Journal of Pharmaceutics and Biopharmaceutics, 2000; 50(1):161-177. https://doi.org/10.1016/S0939-6411(00)00087-4 PMid:10840199

41. Mehnert W, Mäder K, Solid lipid nanoparticles: Production, characterization and applications, Advanced Drug Delivery Reviews, 2001; 47(2-3):165-196. https://doi.org/10.1016/S0169-409X(01)00105-3 PMid:11311991

42. Müller RH, Radtke M, Wissing SA, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Advanced Drug Delivery Reviews, 2002; 54(S1):S131-S155. https://doi.org/10.1016/S0169-409X(02)00118-7 PMid:12460720

43. Souto EB, Müller RH, Investigation of the factors influencing the incorporation model of clotrimazole in SLN and NLC using DSC and X-ray studies, International Journal of Pharmaceutics, 2006; 307(2):232-238.

44. Jenning V, Thünemann AF, Gohla SH, Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids, International Journal of Pharmaceutics, 2000; 199(2):167-177. https://doi.org/10.1016/S0378-5173(00)00378-1 PMid:10802410

45. Pardeike J, Hommoss A, Müller RH, Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products, International Journal of Pharmaceutics, 2009; 366(1-2):170-184. https://doi.org/10.1016/j.ijpharm.2008.10.003 PMid:18992314

46. Wissing SA, Kayser O, Müller RH, Solid lipid nanoparticles for parenteral drug delivery, Advanced Drug Delivery Reviews, 2004; 56(9):1257-1272. https://doi.org/10.1016/j.addr.2003.12.002 PMid:15109768

47. Kaur IP, Bhandari R, Bhandari S, Kakkar V, Potential of solid lipid nanoparticles in brain targeting, Journal of Controlled Release, 2008; 127(2):97-109. https://doi.org/10.1016/j.jconrel.2007.12.018 PMid:18313785

48. Mukherjee S, Ray S, Thakur RS, Solid lipid nanoparticles: A modern formulation approach in drug delivery system, Indian Journal of Pharmaceutical Sciences, 2009; 71(4):349-358. https://doi.org/10.4103/0250-474X.57282 PMid:20502539 PMCid:PMC2865805

49. Shah RM, Eldridge D, Palombo EA, Harding IH, Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique, Journal of Colloid and Interface Science, 2014; 428:286-294. https://doi.org/10.1016/j.jcis.2014.04.057 PMid:24910064

50. Müller RH, Radtke M, Wissing SA, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Advanced Drug Delivery Reviews, 2002; 54(S1):S131-S155. https://doi.org/10.1016/S0169-409X(02)00118-7 PMid:12460720

51. Mehnert W, Mäder K, Solid lipid nanoparticles: Production, characterization and applications, Advanced Drug Delivery Reviews, 2001; 47(2-3):165-196. https://doi.org/10.1016/S0169-409X(01)00105-3 PMid:11311991

52. Mukherjee S, Ray S, Thakur RS, Solid lipid nanoparticles: A modern formulation approach in drug delivery system, Indian Journal of Pharmaceutical Sciences, 2009; 71(4):349-358. https://doi.org/10.4103/0250-474X.57282 PMid:20502539 PMCid:PMC2865805

53. Prajapati SK, Maurya SD, Das MK, Tilak VK, Verma KK, Dhakar RC, Dendrimers in drug delivery, diagnosis and therapy: basics and potential applications, Journal of Drug Delivery and Therapeutics. 2016;6(1):67-92 https://doi.org/10.22270/jddt.v6i1.1190

54. Kakkar V, Muppu SK, Chopra K, Kaur IP, Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin, Molecular Nutrition & Food Research, 2013; 57(9):1550-1556.

55. Battaglia L, Serpe L, Foglietta F, Muntoni E, Gallarate M, Del Grosso E, Solid lipid nanoparticles for drug delivery: Assessment of toxicity and in vivo biodistribution, International Journal of Nanomedicine, 2018; 13:6247-6261. https://doi.org/10.1016/B978-0-12-813687-4.00007-4

56. Tapeinos C, Battaglini M, Ciofani G, Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases, Journal of Controlled Release, 2017; 264:306-332. https://doi.org/10.1016/j.jconrel.2017.08.033 PMid:28844756 PMCid:PMC6701993

57. Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V, Nanostructured lipid carriers: Promising drug delivery systems for future clinics, Nanomedicine, 2016; 12(1):143-161. https://doi.org/10.1016/j.nano.2015.09.004 PMid:26410277

58. Doktorovova S, Souto EB, Silva AM, Lipid nanoparticles: A comprehensive overview on topical delivery and enhancement of transdermal absorption, Expert Opinion on Drug Delivery, 2014; 11(4):599-617.

59. Müller RH, Radtke M, Wissing SA, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Advanced Drug Delivery Reviews, 2002; 54(S1):S131-S155. https://doi.org/10.1016/S0169-409X(02)00118-7 PMid:12460720

60. Tapeinos C, Battaglini M, Ciofani G, Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases, Journal of Controlled Release, 2017; 264:306-332. https://doi.org/10.1016/j.jconrel.2017.08.033 PMid:28844756 PMCid:PMC6701993

61. Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V, Nanostructured lipid carriers: Promising drug delivery systems for future clinics, Nanomedicine, 2016; 12(1):143-161. https://doi.org/10.1016/j.nano.2015.09.004 PMid:26410277

62. Mehnert W, Mäder K, Solid lipid nanoparticles: Production, characterization and applications, Advanced Drug Delivery Reviews, 2012; 64(Suppl):83-101. https://doi.org/10.1016/j.addr.2012.09.021